Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global OTC leader grows in China

This article was originally published in The Tan Sheet

Executive Summary

Japanese firm Taisho Pharmaceutical, an OTC manufacturer and a majority stakeholder of Chinese firm Shanghai Dazhengli Health Care, purchased the 15 percent of the firm held by the Guan Shen Yuan Group for 14.7994 million yuan ($2.2 million at Sept. 24 conversion rates). Taisho set up Shanghai Dazhengli Health Care in 1997 to sell its Libogen products in China. Shanghai Dazhengli can produce more than 20 million bottles of Lipovitan D nutrient drink annually. Taisho wants to expand its production and sales in China from Shanghai

You may also be interested in...



Sales Already Growing As Vascepa Secures Cardio Approval

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

Topics

UsernamePublicRestriction

Register

PS102144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel